GlobeNewswire

FDA Approves First-Of-Its-Kind Percept™ PC Neurostimulator with BrainSense™ Technology

Share

 Next-Generation Technology Makes Percept™ the First and Only DBS System with Ability to Capture Patient-Specific Brain Signals 
for More Personalized, Data-Driven Treatment 

DUBLIN, June 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announces it received Food and Drug Administration (FDA) approval for the Percept™ PC Deep Brain Stimulation (DBS) system. BrainSense™ technology makes Percept the first and only DBS neurostimulation system with the ability to chronically capture and record brain signals while delivering therapy to patients with neurologic disorders associated with Parkinson’s disease, essential tremor, dystonia, epilepsy or obsessive-compulsive disorder (OCD). Physicians can now track patient brain signals and correlate these with patient-recorded actions or experiences, such as symptoms, side-effects, or medication intake. This enables more personalized, data-driven neurostimulation treatment.

Mayo Clinic in Rochester, Minn., will be the first in the United States to implant the newly approved device. “Our goal is for patients to regain independence, and we know that DBS can significantly improve motor function in people with Parkinson’s disease compared to standard medication alone,” said Bryan Klassen, M.D., neurologist, Mayo Clinic. “We can now more precisely tailor therapy to the individual needs of each patient based on data from neuronal activity.”

DBS is an individualized therapy delivered from a small pacemaker-like device, placed under the skin of the chest or abdomen, to send electrical signals through very thin wires (leads) to a targeted area in the brain related to the symptoms of a neurological disorder, such as Parkinson’s disease.

“With movement disorders like Parkinson’s disease, even sharing a meal and holding utensils can be a challenge,” said John L. Lehr, president and chief executive officer of the Parkinson’s Foundation. “We’re excited by new treatments and clinical advancements that let people with Parkinson’s live fuller, more complete, lives.”

In addition to BrainSense technology, the Percept PC DBS system features several leading-edge innovations, including:

  • The only DBS system eligible for 3T and 1.5T full-body MRI scans, providing patients access to cutting-edge medical imaging
  • Smart battery for personalized prediction of remaining battery life providing elevated peace of mind while planning for device replacement
  • Improved battery longevity compared to Medtronic’s Activa™ PC neurostimulator (when using similar settings and functionality) in a smaller (reduced volume), ergonomic design for patient comfort
  • Low pulse width (duration of the pulse), providing expanded stimulation options
  • Enhanced Patient Programmer leveraging a user-friendly, custom-configured Samsung mobile device that allows patients to manage their therapy easily
  • Designed to facilitate expanded capabilities in the future via software upgrades – to prepare for what’s next in DBS

“There is nothing that can replace clinical judgement in treating patients. For the first time, this technology gives clinicians feedback directly from the DBS patient’s brain,” said Mike Daly, vice president and general manager of the Brain Modulation business, which is part of the Restorative Therapies Group at Medtronic. “With such data-driven, patient-specific insights, we believe it can change the standard of care.”

For further information on the Percept PC Neurostimulator with Brainsense Technology, please visit: Medtronic.com/Percept.

About Medtronic DBS Therapy
DBS therapy is currently approved in many locations around the world, including the United States and Europe, for the treatment of recent and longer-standing Parkinson's disease, essential tremor, primary dystonia, the disabling symptoms of epilepsy and treatment-resistant obsessive-compulsive disorder.

DBS therapy uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver electrical stimulation to precisely targeted areas of the brain as adjunctive treatment for several neurological disorders. Medtronic was the first in the United States to offer full-body MR Conditional DBS systems for patients to have safe scans anywhere on the body under certain conditions. Since 1987, more than 175,000 Medtronic DBS devices have been implanted worldwide for movement disorders and other indications.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-



David T. Young
Public Relations
+1-774-284-2746

Ryan Weispfenning
Investor Relations
+1-763-505-4626

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Election Committee for Eolus Vind AB appointed16.7.2020 13:00:00 CESTPress release

Hässleholm, Sweden, July 16, 2020 The Election committee consists of the following members: Hans-Göran Stennert, Chairman of the Board, Eolus Vind AB. Ingvar Svantesson, appointed by Domneåns Kraftaktiebolag. Hans Gydell, appointed by Hans-Göran Stennert. Hans Johansson, appointed by Åke Johansson. According to a decision of the Annual General Meeting of January 25, 2020, the Election Committee shall consist of one member appointed by each of the three largest shareholders and the Chairman of the Board. The appointment of the Election Committee has been carried out in such a manner that, Hans-Göran Stennert, Chairman of the Board of Eolus, on the basis of the Euroclear list of registered shareholders as of 31 May 2020, has contacted the largest known shareholders in the company, who have been invited to each propose a representative to the Election Committee. After such contacts, the Election Committee has been appointed. In total, approximately 34.3 percent of the votes are represente

Valberedning för Eolus Vind AB utsedd16.7.2020 13:00:00 CESTPressemelding

Hässleholm den 16 juli 2020 Valberedningen består av följande ledamöter: Hans-Göran Stennert, styrelseordförande i Eolus Vind AB. Ingvar Svantesson, utsedd av Domneåns Kraftaktiebolag. Hans Gydell, utsedd av Hans-Göran Stennert. Hans Johansson, utsedd av Åke Johansson. Enligt beslut på årsstämman den 25 januari 2020 skall valberedningen bestå av en ledamot utsedd av envar av de tre röstmässigt största ägarna jämte styrelseordföranden. Tillsättningen av valberedningen har skett genom att Eolus styrelseordförande Hans-Göran Stennert på grundval av bolagets, av Euroclear tillhandahållna, förteckning över registrerade aktieägare per den 31 maj 2020 kontaktat de för bolaget största kända ägarna, vilka uppmanats att var och en föreslå en representant till valberedningen. Efter sådana kontakter har valberedningen utsetts. Totalt representeras cirka 34,3 procent av rösterna i valberedningen. Valberedningens uppgift är att inför årsstämman 2021 framlägga förslag avseende antal styrelseledamöter

UPM permanently closes its Chapelle newsprint mill16.7.2020 10:00:00 CESTPress release

(UPM, Helsinki, 16.07.2020 at 11:00 EET) – UPM will permanently cease production at its Chapelle newsprint mill in Grand-Couronne, France today. The consultation process with employee representatives was completed on June 15th, 2020 according to French legislation and approved by French authorities on July 15th, 2020. The closure impacts 228 people. UPM offers support to employees in order to alleviate the effects caused by staff reductions in relation to the closing of the mill. With the closure of the mill UPM will reduce a total of 240.000 tonnes of its newsprint paper capacity. “After UPM announced the intention to sell the Chapelle mill in September we started an active sales process and have been in discussions with interested parties since. However, we have not received binding offers by potential buyers. Consequently, we decided to close the mill, while at the same time working with employee representatives to mitigate the social impact on our employees. We remain committed to

Invitation to UPM’s webcast and press conference on half-year financial report 202016.7.2020 09:00:00 CESTPress release

(UPM, Helsinki, 16 July 2020 at 10:00 EET) – UPM will publish its half-year financial report 2020 on 23 July 2020 at 09:30-10:00 EET. After publishing the report will be available on company's website at www.upm.com. A webcast and a conference call for analysts and investors in English language begins at 13:15 EET. UPM’s financial results will be presented by the President and CEO Jussi Pesonen and CFO Tapio Korpeinen. All participants can view the webcast online at www.upm.com or through this link, but participants who wish to ask questions must attend the conference call by dialling a number in the list below: Conference call title: UPM Interim Report for January – June 2020 International telephone numbers: Australia Toll: +61 284058549 Austria Toll: +43 19287907 Belgium Toll: +32 24035814 Denmark Toll: +45 35445577 Finland Toll: +358 981710310 France Toll: +33 170750711 Germany Toll: +49 6913803430 Hong Kong Toll: +852 30600225 India Toll: +91 2271279610 Ireland Toll: +353 14311252

CellaVision AB: God lönsamhet trots negativ covid-19-effekt16.7.2020 08:20:00 CESTPressemelding

Informationen lämnades för offentliggörande 2020-07-16 kl 08.20 1 april–30 juni 2020 Nettoomsättningen ökade med 5% till 118,0 MSEK (112,4).Organiskt minskade omsättningen med 15% (+18).EBITDA uppgick till 36,2 MSEK (41,3).EBITDA-marginalen uppgick till 31% (37).Resultatet före skatt uppgick till 34,4 MSEK (37,9).Resultat per aktie före och efter utspädning uppgick till 1,14 SEK (1,27).Kassaflödet från den löpande verksamheten uppgick till 34,1 MSEK (17,3). 1 januari–30 juni 2020 Nettoomsättningen ökade med 17% till 252,5 MSEK (216,3). Organiskt minskade omsättningen med 8% (+24). EBITDA uppgick till 77,4 MSEK (79,6). EBITDA-marginalen uppgick till 31% (37). Resultatet före skatt uppgick till 59,8 MSEK (72,8). Resultat per aktie före och efter utspädning uppgick till 1,99 SEK (2,42). Kassaflödet från den löpande verksamheten uppgick till 49,5 MSEK (68,4). Väsentliga händelser relaterade till covid-19 Bolaget räknar med att covid-19-pandemin kommer att ha en betydande negativ påverkan p

CellaVision AB: Good profitability despite negative COVID-19-effect16.7.2020 08:20:00 CESTPress release

The information was submitted for publication at 08.20 CET on July 16, 2020 1 April -30 June 2020 Net sales increased by 5% to SEK 118.0 million (112.4).Sales decreased organically by 15% (+18).EBITDA amounted to SEK 36.2 million (41.3).EBITDA margin amounted to 31% (37).Profit before tax amounted to SEK 34.4 million (37.9).Earnings per share before and after dilution were SEK 1.14 (1.27).Cash flow from operating activities amounted to SEK 34.1 million (17.3). 1 January-30 June 2020 Net sales increased by 17% to SEK 252.5 million (216.3).Sales decreased organically by 8% (+24).EBITDA amounted to SEK 77.4 million (79,6). EBITDA margin amounted to 31% (37).Profit before tax amounted to SEK 59.8 million (72.8).Earnings per share before and after dilution were SEK 1.99 (2.42).Cash flow from operating activities amounted to SEK 49.5 million (68.4). Significant events related to COVID-19 The company expects the COVID-19 pandemic to have a significant negative impact on CellaVision's sales an